China Resources Double-Crane Pharmaceutical Co Ltd - Asset Resilience Ratio
China Resources Double-Crane Pharmaceutical Co Ltd (600062) has an Asset Resilience Ratio of 1.18% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2023)
This chart shows how China Resources Double-Crane Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check China Resources Double-Crane Pharmaceuti (600062) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down China Resources Double-Crane Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600062 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥200.64 Million | 1.18% |
| Total Liquid Assets | CN¥200.64 Million | 1.18% |
Asset Resilience Insights
- Limited Liquidity: China Resources Double-Crane Pharmaceutical Co Ltd maintains only 1.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
China Resources Double-Crane Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare China Resources Double-Crane Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for China Resources Double-Crane Pharmaceutical Co Ltd (2000–2023)
The table below shows the annual Asset Resilience Ratio data for China Resources Double-Crane Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.03% | CN¥-4.88 Million ≈ $-714.09K |
CN¥15.43 Billion ≈ $2.26 Billion |
-1.42pp |
| 2022-12-31 | 1.38% | CN¥200.49 Million ≈ $29.34 Million |
CN¥14.48 Billion ≈ $2.12 Billion |
-4.49pp |
| 2021-12-31 | 5.88% | CN¥803.58 Million ≈ $117.59 Million |
CN¥13.68 Billion ≈ $2.00 Billion |
-0.99pp |
| 2020-12-31 | 6.86% | CN¥851.95 Million ≈ $124.67 Million |
CN¥12.42 Billion ≈ $1.82 Billion |
+0.14pp |
| 2019-12-31 | 6.72% | CN¥758.14 Million ≈ $110.94 Million |
CN¥11.28 Billion ≈ $1.65 Billion |
-1.80pp |
| 2018-12-31 | 8.53% | CN¥878.68 Million ≈ $128.58 Million |
CN¥10.31 Billion ≈ $1.51 Billion |
+1.69pp |
| 2017-12-31 | 6.83% | CN¥644.75 Million ≈ $94.35 Million |
CN¥9.44 Billion ≈ $1.38 Billion |
+5.01pp |
| 2016-12-31 | 1.82% | CN¥150.22 Million ≈ $21.98 Million |
CN¥8.24 Billion ≈ $1.21 Billion |
-3.44pp |
| 2015-12-31 | 5.26% | CN¥408.65 Million ≈ $59.80 Million |
CN¥7.76 Billion ≈ $1.14 Billion |
-2.29pp |
| 2014-12-31 | 7.55% | CN¥500.00 Million ≈ $73.17 Million |
CN¥6.62 Billion ≈ $968.61 Million |
+7.55pp |
| 2005-12-31 | 0.00% | CN¥120.00K ≈ $17.56K |
CN¥3.81 Billion ≈ $558.00 Million |
+0.00pp |
| 2001-12-31 | 0.00% | CN¥2.60K ≈ $380.46 |
CN¥2.75 Billion ≈ $401.87 Million |
-6.63pp |
| 2000-12-31 | 6.63% | CN¥98.38 Million ≈ $14.40 Million |
CN¥1.48 Billion ≈ $217.18 Million |
-- |
About China Resources Double-Crane Pharmaceutical Co Ltd
China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure, blood sugar, injection, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 an… Read more